FDA’s Zuckerman Supports Idea Of National Percutaneous Valve Registry
This article was originally published in The Gray Sheet
Executive Summary
The development of percutaneous heart valves would benefit from a centralized postmarket registry based on standardized adverse event definitions, according to participants in a recent FDA workshop
You may also be interested in...
Industry Presents Wish List For DES Guidance At CRT Conference
FDA's forthcoming guidance on drug-eluting stents should provide specific requirements for preclinical, clinical and postmarket studies to help manufacturers get safe products to market quickly, according to stakeholders
INTERMACS Registry Will Light The Way To Earlier VAD Therapy – Editorial
The ongoing INTERMACS registry holds the key to expanding the usefulness of ventricular assist devices from just extending life to improving the quality of life, according to Lynne Warner Stevenson, cardiac surgeon at Brigham and Women's Hospital, Boston
Drug-Eluting Stent Panelists Could Not Agree On Definition Of Thrombosis
FDA advisory panel members examining the risks of thrombosis in on- and off-label use of drug-eluting stents earlier this month could not reach a consensus on which definition of thrombosis to use